Codexis, CDXS, Company Profile 

We engineer enzymes for biosolutions that benefit human health and environmental health. From developing biocatalysts for sustainable pharmaceutical manufacturing, to engineering enzymes for effective disease treatments and accurate molecular diagnostics, we aim to create a brighter future. This unified vision is what drives us to challenge what is possible. 

Powering enzyme engineering 

Our proprietary CodeEvolver® technology platform has the power to revolutionize enzyme performance, tailoring it  for specific applications and processes. Leveraging advanced machine-learning tools with complex molecular, cellular, and bioanalytical workflows, we design, screen, and analyze libraries of thousands of enzyme variants in high throughput, sequencing each variant and correlating its sequence with its performance. 

Content-rich libraries are screened under real-world conditions that yield dense datasets, with multiple parameters optimized in parallel. The resulting evolved variants often have a combination of enhanced properties, such as increased activity, specificity, stability, and expression. These enhanced properties translate into improved technical performance in the intended application and generate a return on investment in commercial settings. 

Pharmaceutical Manufacturing 

The CodeEvolver® technology platform enables the discovery of biocatalysts for the manufacture of small molecule pharmaceuticals, with greatly improved traits including activity, selectivity, and stability. When combined into consecutive enzymatic conversions, the biocatalytic cascades can accomplish difficult chemistry under mild reaction conditions, with minimal waste generation and attractive economics. We currently have 18 commercial API programs, a further 18 in Phase II/III studies, three platform licenses, and over 50 programs in research and early clinical phases. 

Life Sciences 

Enzymes play a critical role in life science workflows. Using the CodeEvolver® technology platform, we have developed a novel engineered DNA ligase for NGS with superior ligation efficiency, and an RNA polymerase to produce quality mRNA at commercial scale. The CodeEvolver® technology platform underpins the key innovations behind the new Enzyme-Catalyzed Oligonucleotide Synthesis ECO SynthesisTM technology, which promises to disrupt existing phosphoramidite-based processes.